Editas Medicine Q3 net loss narrows, beats expectations

Editas Medicine

10/11/2025 12:08

Overview

Editas Q3 net loss decreases to $25.1 mln, beating analyst expectations

Collaboration revenue rises to $7.5 mln, driven by BMS milestone achievement

Company extends cash runway into Q3 2027, supporting EDIT-401 progression

Outlook

Editas plans to submit IND/CTA for EDIT-401 by mid-2026

Company aims for initial human proof-of-concept data for EDIT-401 by end-2026

Editas extends cash runway into Q3 2027, supporting EDIT-401 progression

Result Drivers

BMS MILESTONE - Collaboration revenue increase attributed to milestone achievement under BMS agreement

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration and other research and development revenue
$7.50 mln
Q3 EPS
-$0.28
Q3 Net Income
Beat
-$25.12 mln
-$28.10 mln (11 Analysts)
Q3 Basic EPS
-$0.28
Q3 Operating Expenses
$32.09 mln
Q3 Operating Income
-$24.55 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

Wall Street's median 12-month price target for Editas Medicine Inc is $4.00, about 38.2% above its November 7 closing price of $2.47

Press Release: ID:nGNX278KVY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)